A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-cohort, multi-center Phase I clinical trial to evaluate the
efficacy and safety of MGD013 in ① Cohort 1: patients with unresectable, recurrent or
metastatic melanoma who have failed prior immune checkpoint inhibitor therapy; ② Cohort 2:
patients with untreated, unresectable recurrent or metastatic, mucosal or acral lentiginous
melanoma.